Cardiovascular disease and cognitive function
Conditions
Interventions
Case series:no
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1. All selected patients meet the primary prevention and secondary prevention standards for cardiovascular disease by taking statins; 2. Have sufficient visual and auditory discrimination ability to undergo cognitive assessment; 3. The mental state and intelligence are normal, which can cooperate with the development of the cognitive scale assessment work; 4. Informed consent and voluntary interview.
Exclusion criteria
Exclusion criteria: 1. Hearing, disturbance of consciousness, severe mental illness or history of mental illness; 2. Patients with diagnosed or suspected cognitive impairment (in addition to organic diseases, also include neurasthenia, hysteria, depression, schizophrenia, mania, reactive psychosis, etc.), dementia High-risk population (stroke patients) and dementia patients: Alzheimer's disease patients diagnosed; patients with other dementia diseases such as Parkinson's disease, Huntington's disease, vascular dementia or frontotemporal dementia; brain tumors, bacteria Meningitis and other brain infections, encephalitis, brain degeneration, traumatic brain injury, epilepsy, schizophrenia, history of electrical shock treatment, cognitive impairment related to mental retardation, autism, Down syndrome or delirium; 3. People who are allergic to statins or any component of statins; 4. Patients with active liver disease, including patients with unexplained persistent elevation of serum transaminase and any serum transaminase elevation exceeding 3 times the upper limit of normal value (ULN); patients with decompensated cirrhosis and acute liver failure; biliary occlusion Patient; Patients with severe renal impairment (creatinine clearance <30 ml / min); 6. Patients with myopathy (including myositis); 7. Patients who are concurrently using cyclosporin; 8. During pregnancy, breastfeeding, and women who may become pregnant without proper contraception; 9. Patients with malignant tumors and end-stage disease (end-stage survival time <1 year); 10. Patients who cannot participate in follow-up; 11. Those who are unwilling to accept this investigation or cannot cooperate for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMSE or MoCa Cognitive Assessment Scale; | — |
Countries
China
Contacts
Public ContactZhang Jin
The First Hospital of Lanzhou University
Outcome results
None listed